Russia registers new drug targeting aggressive breast and ovarian cancers

Russia's Ministry of Health has registered a new drug called 'Elivosa' for the treatment of aggressive and advanced forms of breast and ovarian cancer.

The medication is based on the active ingredient fuzuloparib and belongs to the class of selective PARP enzyme inhibitors. It is a targeted therapy developed by Russian pharmaceutical company Petrovax Pharm in collaboration with Chinese partners. There are future plans to fully localize its production cycle at the company's facilities, according to Russia Today.

This development comes as part of ongoing scientific efforts to address a complex medical challenge facing oncologists. Medical data indicates that around 70% of ovarian cancer patients experience relapse within three years, even after successful initial treatment.